Skip to main content

and
  1. Article

    Open Access

    The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

    Preclinical studies have suggested that epigenetic therapy could enhance immunogenicity of cancer cells. We report the results of the PEMDAC phase 2 clinical trial (n = 29; NCT02697630) where the HDAC inhibitor e...

    Lars Ny, Henrik Jespersen, Joakim Karlsson, Samuel Alsén in Nature Communications (2021)